[
  {
    "ts": null,
    "headline": "Dexcom receives FDA warning letter for two U.S. manufacturing facilities",
    "summary": "The warning letter identified issues in manufacturing processes and quality management system at Dexcom's facilities in San Diego, California and Mesa, Arizona.  The company did not provide details about how many observations were made at the two sites, but said it does not \"expect a material impact\" from the letter to its manufacturing capacity or its sales guidance for fiscal year 2025.",
    "url": "https://finnhub.io/api/news?id=30b6b11f2d2e62db1a535729f48c6761dce7ac3bd775b7f7ef5503de8650ea29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741387910,
      "headline": "Dexcom receives FDA warning letter for two U.S. manufacturing facilities",
      "id": 133190175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "The warning letter identified issues in manufacturing processes and quality management system at Dexcom's facilities in San Diego, California and Mesa, Arizona.  The company did not provide details about how many observations were made at the two sites, but said it does not \"expect a material impact\" from the letter to its manufacturing capacity or its sales guidance for fiscal year 2025.",
      "url": "https://finnhub.io/api/news?id=30b6b11f2d2e62db1a535729f48c6761dce7ac3bd775b7f7ef5503de8650ea29"
    }
  },
  {
    "ts": null,
    "headline": "DexCom Gets FDA Warning Letter After Inspections of Facilities",
    "summary": "DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response.",
    "url": "https://finnhub.io/api/news?id=05f8d2446cefe928deee77fb6f710b31215a3d8e52816bb8606f9fcd32904f33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741386780,
      "headline": "DexCom Gets FDA Warning Letter After Inspections of Facilities",
      "id": 133190176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response.",
      "url": "https://finnhub.io/api/news?id=05f8d2446cefe928deee77fb6f710b31215a3d8e52816bb8606f9fcd32904f33"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Global Growth Strategy Q4 2024 Commentary",
    "summary": "During the fourth quarter, the ClearBridge Global Growth Strategy outperformed its MSCI ACWI benchmark. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=59930a1a9918ccb79efd1b65488418aa3dd6328949c2ef1595ec3cf14694e035",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741322100,
      "headline": "ClearBridge Global Growth Strategy Q4 2024 Commentary",
      "id": 133085717,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1385299427/image_1385299427.jpg?io=getty-c-w1536",
      "related": "DXCM",
      "source": "SeekingAlpha",
      "summary": "During the fourth quarter, the ClearBridge Global Growth Strategy outperformed its MSCI ACWI benchmark. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=59930a1a9918ccb79efd1b65488418aa3dd6328949c2ef1595ec3cf14694e035"
    }
  }
]